Seer reports Q2 EPS (37c), consensus (39c)

Reports Q2 revenue $ $4.01M, consensus $ $5.07M.Launched the Proteograph XT Assay Kit, enabling rapid proteomics across a range of sample types and species with unprecedented resolution and more than doubling the throughput without compromising performance…”While we have faced significant headwinds in the quarter, we continue to firmly believe in the long-term opportunity for our differentiated proteomics technology. We are encouraged by the strong interest we have received on our recent launches of the Proteograph XT Assay Kit and STAC and by the data we continue to see our customers generating,” said Omid Farokhzad, CEO and President. “Additionally, we are taking actions to lower barriers to adoption and navigate headwinds. We are focused on laying the foundation for long-term growth and I continue to be bullish about our present and future opportunities.”